Moderna Inc. (MRNA) and Mitsubishi Tanabe Pharma Corporation have partnered to jointly promote Moderna's mRNA respiratory vaccine portfolio in Japan, including Moderna's COVID-19 vaccine, Spikevax.
As per the agreement, Moderna will handle the manufacturing, sales, medical education and distribution of its mRNA respiratory vaccines. The companies will engage in activities to enable broad access to Moderna's mRNA respiratory portfolio to have the maximum impact on public health in Japan.
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.